FDA Panel Review Not Necessary For Iterum's Antibiotic, All Eyes On July 25

Iterum Therapeutics plc (ITRM) has been notified by the FDA that an Advisory Committee meeting to review the company's new drug application for Sulopenem etzadroxil/probenecid is no longer necessary.

from RTT - Top Story https://ift.tt/3oVWoQA
via IFTTT